Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Mr Aaron Prendergast

Back to Search
Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS et al. ( 2022 ) . Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder . European Urology vol. 82 , ( 2 ) 212 - 222 .
Powles T, Mendez-Vidal MJ, Rodriguez-Vida A, Pérez-Valderrama B, Esteban E, Thistlethwaite F, Patel PM, Anido Herranz U et al. ( 2022 ) . CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer . Journal of Clinical Oncology vol. 40 , ( 17_suppl ) lba4503 - lba4503 .
Ng K, Prendergast A, Carter A, Yogeswaran Y, Alexander SB, Rudman S, Wong HH, Alifrangis C et al. ( 2022 ) . GAMMA: Results from a phase II study for relapsed germ cell tumors using an oxaliplatin-based treatment regimen . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 417 - 417 .
Szabados B, Prendergast A, Jackson-Spence F, Choy J, Powles T ( 2021 ) . Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer . European urology oncology vol. 4 , ( 6 ) 943 - 947 .
Cathcart P, Ribeiro L, Moore C, Ahmed HU, Leslie T, Arya M, Orczyk C, Hindley RG et al. ( 2021 ) . Outcomes of the RAFT trial: robotic surgery after focal therapy . BJU International vol. 128 , ( 4 ) 504 - 510 .
Schmid P, Bofill FJS, Bermejo B, Phillips M, Wheatley D, Neus F, Schem C, Stradella A et al. ( 2021 ) . 123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer . Annals of Oncology vol. 32 , s411 - s412 .
Schmid P, Gomez-Pardo P, Wheatley D, Roy P, Krabisch P, Thill M, Ledwidge S, Thompson A et al. ( 2021 ) . 208P ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC . Annals of Oncology vol. 32 , s449 - s450 .
Szabados B, Rodriguez-Vida A, Durán I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA et al. ( 2021 ) . Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial . European urology oncology vol. 4 , ( 3 ) 456 - 463 .
Suarez Rodriguez C, Larkin J, Patel PM, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2021 ) . Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4511 - 4511 .
Schmid P, Kockx M, Kim S-B, Wheatley D, Phillips MM, Hoffmann O, Blohmer JU, Im S-A et al. ( 2021 ) . Abstract PD14-06: Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer . Cancer Research . vol. 81 ,
Schmid P, Kockx M, Kim S-B, Wheatley D, Phillips MM, Hoffmann O, Blohmer JU, Im S-A et al. ( 2021 ) . Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER plus primary breast cancer . CANCER RESEARCH . vol. 81 ,
Choy J, Rodriguez CS, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F et al. ( 2020 ) . 69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups . Annals of Oncology vol. 31 ,
Powles T, Szabados B, Castellano D, Rodriguez-Vida A, Valderrama B, Crabb S, Van Der Heijden M, Pous A et al. ( 2020 ) . CtDNA as a predictor of outcome in patients treated with neoadjuvant atezolizumab in muscle invasive urothelial cancer . Urologic Oncology Seminars and Original Investigations vol. 38 , ( 12 )
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al. ( 2020 ) . Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer . Nature Communications vol. 11 , ( 1 )
Kocher HM, Basu B, Froeling FE, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al. ( 2020 ) . STARPAC clinical trial . Pancreatology vol. 20 , ( 8 )
Szabados BE, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS, Pous AF, Gravis G, Herranz UA et al. ( 2020 ) . 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis . Annals of Oncology vol. 31 ,
Cathcart P, Moore C, Ahmed H, Leslie T, Arya M, Hindley R, Cahill F, Prendergast A et al. ( 2020 ) . PT058 Functional outcomes from the Robotic surgery After Focal Therapy (RAFT) clinical trial . European Urology Open Science vol. 19 ,
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2020 ) . Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7) . Nature Medicine vol. 26 , ( 6 )
Szabados B, Kockx M, Van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font A et al. ( 2020 ) . MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,
Szabados B, Kockx M, Van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font A et al. ( 2020 ) . MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 541 - 541 .
Suarez Rodriguez C, Larkin JMG, Patel P, Perez Valderrama B, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2020 ) . Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,
Suarez Rodriguez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2020 ) . Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 619 - 619 .
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH et al. ( 2020 ) . Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial . Journal of Clinical Oncology vol. 38 , ( 5 ) 423 - 433 .
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2019 ) . Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Nature Medicine vol. 25 , ( 11 ) 1706 - 1714 .
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al. ( 2019 ) . Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial . JAMA Oncology vol. 5 , ( 11 ) 1556 - 1563 .
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al. ( 2019 ) . 700PSTAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer . Annals of Oncology vol. 30 , ( Supplement_5 )
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al. ( 2019 ) . STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer . ANNALS OF ONCOLOGY . vol. 30 ,
Cross AJ, Wooldrage K, Robbins EC, Kralj-Hans I, MacRae E, Piggott C, Stenson I, Prendergast A et al. ( 2019 ) . Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: A diagnostic accuracy and cost-effectiveness study . Gut vol. 68 , ( 9 ) 1642 - 1652 .
Szabados B, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A et al. ( 2019 ) . 1121 Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscle-invasive urothelial carcinoma of the bladder . European Urology Open Science vol. 18 , ( 1 )
Powles T, Larkin JMG, Patel P, Pérez-Valderrama B, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2019 ) . A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO) . Journal of Clinical Oncology . vol. 37 , 545 - 545 .
Atkin W, Cross AJ, Kralj-Hans I, Macrae E, Piggott C, Pearson S, Wooldrage K, Brown J et al. ( 2019 ) . Faecal immunochemical tests versus colonoscopy for post-poly pectomy surveillance: An accuracy, acceptability and economic study . Health Technology Assessment vol. 23 , ( 1 ) I - 84 .
Powles T, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font Pous A, Gravis G, Anido Herranz U et al. ( 2018 ) . A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 4506 - 4506 .
Schmid P, Abraham J, Chan S, Wheatley D, Brunt M, Nemsadze G, Baird R, Park YH et al. ( 2018 ) . AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial . Journal of Clinical Oncology . vol. 36 , 1007 - 1007 .
Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . ANNALS OF ONCOLOGY . Conference: ESMO vol. 28 ,
Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . Annals of Oncology vol. 28 ,
Back to Search